SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Interim Management Statement

26 Jul 2016 07:00

RNS Number : 1780F
Victrex PLC
26 July 2016
 
 

 

 

 

26 July 2016

Victrex plc: Interim Management Statement

'On track for H2 improvement'

Victrex plc, an innovative world leader in high performance polymer solutions, today releases its Interim Management Statement for the third quarter (Q3) covering the period 1 April to 30 June 2016.

Performance continued in line with our expectations during Q3. Our core business remains robust, with growth in Aerospace and Automotive, and a steadier performance in Oil & Gas. Our Medical business was in line with the prior year period.

As expected, the Group's overall performance in the quarter was offset by limited volumes in the large Consumer Electronics order during Q3, compared to a strong Q3 2015. As previously communicated, these volumes will be much more back-end loaded into Q4 this year, with second half volumes still expected to be double those in the first half.

For Q3 as a whole, Group revenue was down 6% to £60.6m (Q3 2015: £64.6m), with Group sales volume down 10% to 966 tonnes (Q3 2015: 1,070 tonnes). Excluding Consumer Electronics volumes, overall performance was marginally ahead of the strong Q2.

Cash generation has remained healthy and there have been no significant changes to the Group's financial position since our interim results announcement.

 

Outlook

 

For 2016, our core business remains robust and we continue to focus on cost opportunities. We remain on track for a second half improvement and are comfortable with current expectations for the full year.

 

Variability in end user demand and supply chain dynamics means the Consumer Electronics market continues to offer limited visibility. Our early planning assumptions for 2017 now suggest these volumes will be significantly lower, compared to 2016. We do, however, remain encouraged by medium to longer term growth opportunities within Consumer Electronics and have market-wide development programmes in progress, for both volume and value opportunities. Lower Consumer Electronics volumes in 2017 would improve the Group's sales mix, although it would be less beneficial for operating leverage, reflecting higher fixed costs. Currency for 2017 has now become more supportive, although rates continue to be volatile and hedging is already in place for nearly two-thirds of our FY17 financial year.

 

Victrex remains in a good position for the medium to longer term. The Group has a strategy to further increase our differentiation, a strong pipeline of potentially game-changing projects and a highly cash generative business model.

 

 

 

Enquiries:

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 7809 595831

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

 

Teneo Strategy:

Charles Armitstead +44 (0) 203 603 5220

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the Automotive, Aerospace, Energy, Electronics and Medical markets. Every day, millions of people rely on products or applications which contain our materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we deliver leading edge solutions to shape future performance for our customers and our markets, and to drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSEAKXSADSKEFF
Date   Source Headline
30th Jun 20251:38 pmRNSTotal Voting Rights
30th Jun 20259:13 amRNSDirector Declaration
18th Jun 20257:00 amRNSAppointment of Joint Corporate Broker
3rd Jun 20251:56 pmRNSHolding(s) in Company
2nd Jun 202511:34 amRNSBlock listing Interim Review
2nd Jun 202510:25 amRNSHolding(s) in Company
30th May 20259:50 amRNSTotal Voting Rights
27th May 202512:40 pmRNSHolding(s) in Company
13th May 20253:30 pmRNSDirector/PDMR Shareholding
12th May 20257:00 amRNSVictrex plc – Interim Results 2025
7th May 20257:00 amRNS‘Magma’ advances via TechnipFMC award
30th Apr 202511:00 amRNSTotal Voting Rights
31st Mar 20259:17 amRNSTotal Voting Rights
21st Mar 202510:34 amRNSDirector/PDMR Shareholding
28th Feb 20259:55 amRNSTotal Voting Rights
19th Feb 20259:00 amRNSAdditional Listing
7th Feb 20251:54 pmRNSResult of AGM
7th Feb 20257:00 amRNSAGM and Trading Update
31st Jan 20259:17 amRNSTotal Voting Rights
21st Jan 20251:56 pmRNSHolding(s) in Company
6th Jan 20251:00 pmRNSAnnual Financial Report
31st Dec 20249:00 amRNSTotal Voting Rights
16th Dec 20248:52 amRNSDirector/PDMR Shareholding
11th Dec 20243:07 pmRNSDirector/PDMR Shareholding
10th Dec 202411:46 amRNSDirector/PDMR Shareholding
10th Dec 20249:28 amRNSHolding(s) in Company
3rd Dec 202410:58 amRNSDirector/PDMR Shareholding
3rd Dec 20247:00 amRNSVictrex plc - Preliminary Results 2024
2nd Dec 20249:38 amRNSBlock listing Interim Review
29th Nov 20249:07 amRNSTotal Voting Rights
14th Nov 20249:31 amRNSHolding(s) in Company
31st Oct 202412:25 pmRNSTotal Voting Rights
14th Oct 20243:09 pmRNSHolding(s) in Company
30th Sep 20241:44 pmRNSTotal Voting Rights
27th Sep 20249:22 amRNSHolding(s) in Company
24th Sep 202411:24 amRNSDirector/PDMR Shareholding
17th Sep 20242:00 pmRNSUS FDA approval: Total Knee Study
12th Sep 202411:18 amRNSDirector/PDMR Shareholding
3rd Sep 20244:20 pmRNSHolding(s) in Company
30th Aug 20243:44 pmRNSDirector/PDMR Shareholding
30th Aug 20249:16 amRNSTotal Voting Rights
23rd Aug 20243:18 pmRNSHolding(s) in Company
9th Aug 202410:08 amRNSHolding(s) in Company
5th Aug 20241:56 pmRNSDirector/PDMR Shareholding
2nd Aug 202411:51 amRNSDirector/PDMR Shareholding
1st Aug 20241:20 pmRNSDirector/PDMR Shareholding
31st Jul 202412:20 pmRNSTotal Voting Rights
5th Jul 20242:02 pmRNSDirector/PDMR Shareholding
4th Jul 20247:00 amRNSQ3 Interim Management Statement
28th Jun 20249:52 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.